1. Home
  2. PTLO vs SENS Comparison

PTLO vs SENS Comparison

Compare PTLO & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Portillo's Inc.

PTLO

Portillo's Inc.

HOLD

Current Price

$4.18

Market Cap

323.5M

ML Signal

HOLD

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

HOLD

Current Price

$6.65

Market Cap

301.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTLO
SENS
Founded
1963
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Industrial Machinery/Components
Sector
Consumer Discretionary
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
323.5M
301.2M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
PTLO
SENS
Price
$4.18
$6.65
Analyst Decision
Hold
Strong Buy
Analyst Count
11
4
Target Price
$8.06
$18.38
AVG Volume (30 Days)
1.5M
499.5K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$732,066,000.00
$16,389,000.00
Revenue This Year
$9.02
$74.15
Revenue Next Year
$5.81
$58.60
P/E Ratio
N/A
N/A
Revenue Growth
3.03
19.85
52 Week Low
$3.78
$0.41
52 Week High
$11.82
$8.75

Technical Indicators

Market Signals
Indicator
PTLO
SENS
Relative Strength Index (RSI) 47.51 50.35
Support Level $3.79 $6.40
Resistance Level $4.40 $6.87
Average True Range (ATR) 0.22 0.49
MACD 0.08 -0.03
Stochastic Oscillator 60.25 23.31

Price Performance

Historical Comparison
PTLO
SENS

About PTLO Portillo's Inc.

Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. The company owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, sides and soup, and others.

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

Share on Social Networks: